Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study - Scorecard - MDSpire
Advertisement
Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study
Clinical Scorecard: Effectiveness and Safety of Maintenance Therapy with PARP Inhibitors in Older Patients with Ovarian Cancer: A Retrospective Cohort Analysis from a Single Center
At a Glance
Category
Detail
Condition
Ovarian Cancer
Key Mechanisms
PARP inhibitors target DNA repair mechanisms.
Target Population
Older patients (≥ 65 years) with ovarian cancer.
Care Setting
Single center study at Peking University People’s Hospital.
Key Highlights
35.7% of patients received olaparib, 60.7% received niraparib.
Median progression-free survival (mPFS) was 24 months for first-line maintenance therapy.
Anemia (22.7%) was the most frequent grade 3–4 adverse event in the olaparib group.
Niraparib had a lower termination rate compared to olaparib.
Three clinical factors were predictive of longer PFS in first-line maintenance therapy.
Guideline-Based Recommendations
Diagnosis
Patients included had invasive ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Management
Maintenance therapy with PARP inhibitors (olaparib or niraparib) after achieving CR or PR to platinum-based chemotherapy.
Monitoring & Follow-up
Monitor CA125 levels, BRCA mutation status, and surgical outcomes (R0) for predicting PFS.
Risks
Adverse events include anemia and thrombocytopenia; dose reductions and interruptions were common.
Patient & Prescribing Data
Elderly patients (≥ 65 years) with advanced ovarian cancer.
Long-term PARP inhibitor use was generally well-tolerated.
Clinical Best Practices
Consider geriatric assessment tools for treatment individualization in elderly patients.
Evaluate comorbidities and drug tolerance in elderly patients receiving PARP inhibitors.
